×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CANF – can-fite biopharma ltd american depositary shares, each representing two (2) ordinary shares (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CANF
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
08:05 am
canf
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 [Yahoo! Finance]
Medium
Report
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 [Yahoo! Finance]
3/30
07:20 am
canf
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Medium
Report
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
3/26
09:27 am
canf
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Low
Report
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
3/17
07:47 am
canf
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Medium
Report
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
3/4
10:25 am
canf
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
High
Report
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
3/4
07:25 am
canf
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study [Yahoo! Finance]
High
Report
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study [Yahoo! Finance]
3/4
07:00 am
canf
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Medium
Report
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
2/17
07:00 am
canf
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Low
Report
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
06:07 am
canf
Form EFFECT Can-Fite BioPharma Ltd.
Medium
Report
Form EFFECT Can-Fite BioPharma Ltd.
4/1
06:07 am
canf
Form EFFECT Can-Fite BioPharma Ltd.
Medium
Report
Form EFFECT Can-Fite BioPharma Ltd.
3/31
06:09 am
canf
Form F-3 Can-Fite BioPharma Ltd.
Low
Report
Form F-3 Can-Fite BioPharma Ltd.
3/31
06:04 am
canf
Form POS AM Can-Fite BioPharma Ltd.
Low
Report
Form POS AM Can-Fite BioPharma Ltd.
3/31
06:04 am
canf
Form POS AM Can-Fite BioPharma Ltd.
Low
Report
Form POS AM Can-Fite BioPharma Ltd.
3/30
07:22 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Mar 30
Medium
Report
Form 6-K Can-Fite BioPharma Ltd. For: Mar 30
3/26
10:05 am
canf
Form 20-F Can-Fite BioPharma Ltd. For: Dec 31
Low
Report
Form 20-F Can-Fite BioPharma Ltd. For: Dec 31
3/26
09:29 am
canf
Form 6-K Can-Fite BioPharma Ltd. For: Mar 26
Medium
Report
Form 6-K Can-Fite BioPharma Ltd. For: Mar 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/29
Visiongain Report Claims There is Huge Potential Within the $39bn Dermatological Drugs Market
43.6%
12/26 Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing 30.5%
3/5 Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus 24.5%
9/10 Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays 23.2%
4/13 Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately 22.5%
4/2 Form 6-K/A Can-Fite BioPharma Ltd. For: Apr 02 17.2%
3/11 Form 6-K Can-Fite BioPharma Ltd. For: Mar 11 16.0%
1/3 New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss 12.8%
5/30 Form SC 13D Can-Fite BioPharma Ltd. Filed by: Capital Point Ltd. 9.4%
2/12 Form 6-K Can-Fite BioPharma Ltd. For: Feb 12 8.9%
12/26 Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing 30.5%
3/5 Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus 24.5%
9/10 Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays 23.2%
4/13 Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately 22.5%
4/2 Form 6-K/A Can-Fite BioPharma Ltd. For: Apr 02 17.2%
3/11 Form 6-K Can-Fite BioPharma Ltd. For: Mar 11 16.0%
1/3 New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss 12.8%
5/30 Form SC 13D Can-Fite BioPharma Ltd. Filed by: Capital Point Ltd. 9.4%
2/12 Form 6-K Can-Fite BioPharma Ltd. For: Feb 12 8.9%
TOP News Decliners
5/20
Can-Fite BioPharma Announces $6 Million Registered Direct Offering
-53.0%
10/17 Form 6-K Can-Fite BioPharma Ltd. For: Oct 17 -48.6%
2/10 Can-Fite BioPharma Announces Pricing of $5 Million Public Offering -43.4%
1/9 Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million -19.7%
3/13 Form 6-K Can-Fite BioPharma Ltd. For: Mar 13 -19.4%
10/31 Can-Fite up 36% premarket on advancement of Namodenoson [Seeking Alpha] -19.3%
8/1 Form 6-K Can-Fite BioPharma Ltd. For: Aug 01 -19.2%
4/7 Form 6-K Can-Fite BioPharma Ltd. For: Apr 07 -18.8%
2/27 Form 6-K Can-Fite BioPharma Ltd. For: Feb 27 -16.8%
3/23 Form 6-K Can-Fite BioPharma Ltd. For: Mar 23 -15.3%
10/17 Form 6-K Can-Fite BioPharma Ltd. For: Oct 17 -48.6%
2/10 Can-Fite BioPharma Announces Pricing of $5 Million Public Offering -43.4%
1/9 Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million -19.7%
3/13 Form 6-K Can-Fite BioPharma Ltd. For: Mar 13 -19.4%
10/31 Can-Fite up 36% premarket on advancement of Namodenoson [Seeking Alpha] -19.3%
8/1 Form 6-K Can-Fite BioPharma Ltd. For: Aug 01 -19.2%
4/7 Form 6-K Can-Fite BioPharma Ltd. For: Apr 07 -18.8%
2/27 Form 6-K Can-Fite BioPharma Ltd. For: Feb 27 -16.8%
3/23 Form 6-K Can-Fite BioPharma Ltd. For: Mar 23 -15.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: